Bana Jobe

For rare disease trials, which are already challenging to enroll, the new guidance introduces nuances that speak to broader recruitment trends in orphan drugs. Here's what sponsors should know when approaching "rarified" rare disease protocols.

The awareness, investments, and enthusiasm surrounding vaccine research is at an all-time high. At the same time, challenges in pushing vaccine trials forward remain, and many barriers are more palpable now than ever before.

How biopharma companies can preempt threats to copay assistance with a more comprehensive approach to patient support.

BioPharma companies utilizing patient support hubs that offer wrap-around care have seen dramatic increases in access, affordability and adherence. What used to involve simple patient assistance and therapy access has evolved into dynamic systems that track, anticipate and offer resources to patients.

Health systems have an opportunity to partner with community health centers to reduce medical mistrust among historically marginalized groups, impacting health outcomes and equity.

To improve health equity, clinicians need to develop, showcase, and implement clinical empathy in their care delivery to help rebuild decades of medical mistrust among marginalized groups.

With protected health information (PHI) dispersed across wearables, apps, portals, and other places, more companies than ever have access to sensitive data, and that access comes with serious responsibilities. But businesses need to use data, so this creates a tension – a push and pull between access and security. As organizations attempt to make data less vulnerable, they may also make it less usable. And what good is that?

While the clinical research industry has taken steps toward more diversity, equity, and inclusion (DEI) within research and development, the gains should be taken in the context of the systemic barriers that remain. Despite stakeholders becoming more intentional and determined about trial diversity and FDA guidance to make trials more representative, there is more to be done to put R&D to work for everyone.

When you're expecting a baby, picking a provider is among the first and most important decisions you will make. Naturally, you want to make the perfect choice, but the key isn't finding the best OBGYN and hospital, it's finding the best ones for you.

Psychedelic products are having a renaissance moment. As evidence emerges about their potential for PTSD, depression, cancer-related distress and more, the market for psychedelics could swell from $2 billion in 2020 to $10.75 billion in 2027. With regulators and lawmakers seemingly on board, sponsors have more opportunities than ever to pursue clinical research in this high-velocity area.

Join us as we walk through how to assess your organization’s needs in a drug discount management program, define its structure, and build on its strengths for a more impactful and cost-effective initiative.

First trimester bleeding, while common, can be concerning. Progesterone testing, progestogen therapy and imaging are all tools doctors can use to help.

Will COVID-19 be with us forever? Time will tell. For now, providers should cling to what hasn't changed while they adapt to what has.

When it comes to borderline personality disorder (BPD), two facts should concern clinicians in psychiatry and general practice. The first is that roughly 3 in 4 BPD patients attempt suicide or otherwise engage in self-harm. The second is that BPD is often overlooked and undiagnosed in clinical practice.

In 2022 and beyond, health care executives will continue to explore opportunities that impact payers, providers, patients, and employers – creating meaningful change across priorities, from health equity and value-based care to behavioral health. Download the playbook to find out more about the roles of transition to value-based care, greater integration of behavioral health care, and adoption of virtual care and other modalities.